1. Generics Bulletin
  2. >>Products
  3. >>Value Added Medicines

Sandoz Phases US Epinephrine Entry

 
• By Aidan Fry

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.

Epinephrine
• Source: Shutterstock

Sandoz will use a “phased launch” to introduce its Symjepi (epinephrine) pre-filled syringe in the US. The Novartis division will first roll out the emergency anaphylaxis treatment in the US institutional setting – “an established channel where Sandoz has significant experience and knowledge” – before turning its attention to the retail market.

Hailing its product as “an affordable, single-dose, pre-filled syringe alternative to epinephrine auto-injectors”, Sandoz had previously announced plans to launch...

More from Value Added Medicines

Hyloris Secures US Approval For Avenacy-Partnered RTU Tranexamic Acid

 
• By Adam Zamecnik

After signing a deal with Avenacy at the end of last year, Hyloris has now announced the approval of its intravenous formulation of tranexamic acid, which is used as a hemostatic agent.

The Generics Bulletin Podcast: The Global Generics & Biosimilars Awards 2025

 
• By Dave Wallace and Dean Rudge

With entries now open for the Global Generics & Biosimilars Awards 2025 – which takes place in Frankfurt on Wednesday 29 October – Generics Bulletin’s editors discuss all the key details, including tips for entrants, in our latest podcast.

‘Why Wouldn’t You Use This?’: Teva Plots $2bn LAI Schizophrenia Franchise

 
• By Dean Rudge

Teva has laid out an ambitious goal for its long-acting injectable schizophrenia drugs to grow into a $2bn franchise, ahead of the planned US filing of olanzapine later this year.

Fresenius Adds To Denosumab Competitors In Europe

 
• By Dave Wallace

At a busy meeting of the CHMP, the EMA issued positive opinions for Fresenius Kabi’s denosumab rivals to Prolia and Xgeva, another denosumab biosimilar from Sandoz, a Tecfidera hybrid from Neuraxpharm and a Descovy generic from Viatris. Meanwhile, Ascend has withdrawn a teriparatide filing.

More from Products

Reshaped Xbrane Allies With OneSource For Commercial Biosimilar Manufacturing

 
• By Dean Rudge

Xbrane Biopharma is partnering with India’s OneSource Specialty Pharma to manufacture its biosimilars, including its much-delayed ranibizumab product Ximluci. The move follows a SEK240m funding round and strategic refocus on commercialization after divesting key R&D assets to Alvotech.

Hyloris Secures US Approval For Avenacy-Partnered RTU Tranexamic Acid

 
• By Adam Zamecnik

After signing a deal with Avenacy at the end of last year, Hyloris has now announced the approval of its intravenous formulation of tranexamic acid, which is used as a hemostatic agent.

Regeneron Monitoring Eylea Biosimilar Closely Following Innovative Setbacks

 
• By Dean Rudge

Regeneron says it is closely watching Amgen’s Pavblu 2mg aflibercept biosimilar, which is gaining traction via financial incentives to physicians as “the only differentiator” to its Eylea reference brand. Meanwhile, Regeneron is aiming to boost Eylea HD uptake amid regulatory setbacks.